Table 2 Parasitological characteristics, ANC attendance and use of personal protection according to season
Variables | Dry season, N = 174 | Wet season, N = 182 | ||||||
|---|---|---|---|---|---|---|---|---|
Primigravidity | Secundigravidity | Multigravidity | Total | Primigravidity | Secundigravidity | Multigravidity | Total | |
n = 31 | n = 42 | n = 101 | n = 47 | n = 32 | n = 103 | |||
Parasitological characteristics | ||||||||
Parasitaemia (any level)a | 7 (22.6%) | 10 (23.8%) | 14 (13.9%) | 31 (17.8%) | 7 (14.9%) | 2 (6.3%) | 16 (15.5%) | 25 (13.7%) |
Parasitaemia ≥ 1000/µla | 4 (12.9%) | 2 (4.8%) | 4 (4.0%) | 10 (5.7%) | 5 (10.6%) | 1 (3.1%) | 6 (5.8%) | 12 (6.6%) |
**GMPD/µl (95% CI)a | 1435.7 (412.7–4995.2) | 738.7 (276.0–1976.8) | 478.9 (263.7–869.7) | 705.7 (444.8–1119.5) | 2925.3 (421.0–20,325.6) | Low number of observations | 469.7 (160.3–1376.3) | 876.2 (367.0–2092.2) |
ANC attendance | ||||||||
None | 6 (19.4%) | 14 (35.0%) | 28 (28.0%) | 48 (28.1%) | 3 (6.4%) | 7 (21.9%) | 17 (16.5%) | 27 (14.8%) |
1 | 7 (22.6%) | 11 (27.5%) | 28 (28.0%) | 46 (26.9%) | 8 (17.0%) | 7 (21.9%) | 24 (23.3%) | 39 (21.4%) |
2 | 4 (12.9%) | 3 (7.5%) | 22 (22.0%) | 29 (17.0%) | 6 (12.8%) | 7 (21.9%) | 25 (24.3%) | 38 (20.9%) |
3 | 7 (22.6%) | 7 (17.5%) | 12 (12.0%) | 26 (15.2%) | 16 (34.0%) | 5 (15.6%) | 20 (19.4%) | 41 (22.5%) |
4 or more | 7 (22.6%) | 5 (12.5%) | 10 (10.0%) | 22 (12.9%) | 14 (29.8%) | 6 (18.8%) | 17 (16.5%) | 37 (20.3%) |
Use of personal protective measures | ||||||||
Access to ITN | 23 (74.2%) | 37 (88.1%) | 93 (93.0%) | 153 (88.4%) | 41 (87.2%) | 32 (100%) | 99 (96.1%) | 172 (94.5%) |
Used an ITN the previous night | 21 (67.7%) | 35 (83.3%) | 85 (85.0%) | 141 (81.5%) | 42 (89.4%) | 31 (96.9%) | 100 (97.1%) | 173 (95.1%) |
Mosquito coils | 8 (25.8%) | 9 (21.4%) | 24 (24.0%) | 41 (23.7%) | 10 (21.3%) | 3 (9.4%) | 15 (14.6%) | 28 (15.4%) |
Other spatial repellent | 1 (3.2%) | 0 | 5 (5.0%) | 6 (3.5%) | 4 (8.5%) | 1 (3.1%) | 10 (9.7%) | 15 (8.2%) |
Commercial repellent (topical) | 3 (9.7%) | 5 (11.9%) | 9 (9.0%) | 17 (9.8%) | 8 (17.0%) | 1 (3.1%) | 8 (7.8%) | 17 (9.4%) |
0 dose of IPTp-SP | 6 (19.4%) | 15 (35.7%) | 16 (15.8%) | 37 (21.3%) | 0 | 4 (12.5%) | 7 (6.8%) | 11 (6.0%) |
1 doses of IPTp-SP | 9 (29.0%) | 8 (19.0%) | 35 (34.7%) | 52 (29.9%) | 11 (23.4%) | 8 (25.0%) | 28 (27.2%) | 47 (25.8%) |
2 doses of IPTp-SP | 7 (22.6%) | 4 (9.5%) | 23 (22.8%) | 34 (19.5%) | 12 (25.5%) | 9 (28.1%) | 35 (34.0%) | 56 (30.8%) |
3 or more doses of IPTp-SP | 5 (16.1%) | 8 (19.0%) | 12 (11.9%) | 25 (14.4%) | 20 (42.6%) | 6 (18.8%) | 21 (20.4%) | 47 (25.8%) |
Mean IPTp-SP dose (95% CI) | 1.4 (1.0–1.8) | 1.3 (0.8–1.7) | 1.4 (1.2–1.6) | 1.4 (1.2–1.6) | 2.2 (1.9–2.5) | 1.8 (1.3–2.3) | 1.8 (1.6–2.1) | 1.9 (1.8–2.1) |
Use of anti-malarial drug 2 weeks before the survey | 3 (10.7%) | 6 (15.0%) | 18 (18.4%) | 27 (16.3%) | 7 (14.9%) | 2 (6.3%) | 10 (9.7%) | 19 (10.4%) |